mRESVIA

Overview

mRNA vaccine (mRNA-1345) against respiratory syncytial virus (RSV) — the first mRNA vaccine approved for a disease other than COVID-19, and a key pillar of Moderna's expanding respiratory franchise.

FDA-approved May 2024 for older adults; EU label expanded to adults 18+ in 2026. Small but growing sales as Moderna builds a multi-product respiratory portfolio.

Key Specs